37 completed, 3 terminated, 1 recruiting, 1 suspended. 44 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 44 | Completed 37, Terminated 3, Recruiting 1, Suspended 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 4, Recruiting 1, Suspended 1, Terminated 1 |
Follow Parathyroid Diseases: new trials by email Literature Review of Parathyroid Diseases trials Research Report on Parathyroid Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Parathyroid Allotransplant for Treatment of Hypoparathyroidism Parathyroid Allotransplant - Hypoparathyroidism, Hypoparathyroidism Postprocedural | Phase 1 / Phase 2 | Recruiting | Peter Stock | 3 | 2026-01-15 | 2026-02-27 |
| Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism Single subcutaneous injection, Multiple subcutaneous injection - Hypoparathyroidism | Phase 1 / Phase 2 | Suspended | Peking Union Medical College Hospital | 15 | 2025-11-17 | 2026-09-25 |
| A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism [14C] SHR6508 Injection - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 5 | 2024-12-23 | 2026-03-23 |
| Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo EBP05, Forteo 0.02 mg, EBP11 - Hypoparathyroidism, Osteoporosis | Phase 1 | Completed | Entera Bio Ltd. | 45 | 2023-05-11 | 2026-02-17 |
| A Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508；Placebo - Secondary Hyperparathyroidism | Phase 1 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 54 | 2022-03-10 | 2023-08-08 |
| A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism PCO371, Placebo - Hypoparathyroidism | Phase 1 | Terminated | Chugai Pharmaceutical | 5 | 2020-07-23 | 2021-06-11 |
| Vitamin D Metabolism in Patients With Endocrine Disorders Cholecalciferol 15000 UNT/ML Oral Solution - Pituitary ACTH Hypersecretion, Acromegaly | Phase 1 | Completed | Endocrinology Research Centre, Moscow | 261 | 2019-04-16 | 2022-08-11 |
| Pain Medications Following Thyroidectomy and Parathyroidectomy Non-narcotic group regimen, Narcotic group regimen - Thyroid Disease, Parathyroid Diseases | Phase 1 | Completed | MetroHealth Medical Center | 126 | 2018-11-15 | 2019-12-26 |
| Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects CTAP101 Capsules - Vitamin D Insufficiency, Secondary Hyperparathyroidism | Phase 1 | Completed | OPKO Health, Inc. | 67 | 2018-08-20 | 2019-09-30 |
| A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 Etelcalcetide, Placebo - Secondary Hyperparathyroidism | Phase 1 | Completed | Amgen | 33 | 2018-03-01 | 2020-02-10 |
| Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects rhPTH(1-84) - Hypoparathyroidism | Phase 1 | Completed | Shire | 24 | 2017-05-16 | 2021-06-08 |
| Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism 25mcg rhPTH(1-84), 50mcg rhPTH(1-84), 100mcg rhPTH(1-84) - Hypoparathyroidism | Phase 1 | Completed | Shire | 34 | 2017-04-03 | 2021-05-25 |
| A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis Etelcalcetide - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 1 | Completed | Amgen | 11 | 2017-03-14 | 2019-07-10 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105 Single VS-105/placebo to healthy, Multiple VS-105/placebo to healthy, Multiple VS-105/placebo to HD subjects - Chronic-kidney Disease Stage 5D on Stable Hemodialysis | Phase 1 | Completed | Vidasym, Inc. | 69 | 2017-01-24 | 2019-10-07 |
| Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions NFC-1 - 22q11.2 Deletion Syndrome | Phase 1 | Completed | Aevi Genomic Medicine, LLC, a Cerecor company | 2 | 2016-11-28 | 2022-03-25 |
| One Week Comparison Study of PTH and PTHrP Infusions Parathyroid Hormone-related Protein (1-36), parathyroid hormone (1-34), PTH (1-34) and PTHrP (1-36) - Osteoporosis, Hypercalcemia of Malignancy | Phase 1 | Withdrawn | University of Pittsburgh | 2015-01-01 | 2014-12-05 | |
| Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid CTAP101 Capsules - Breast Cancer, Prostate Cancer | Phase 1 | Completed | OPKO Health, Inc. | 33 | 2014-12-01 | 2019-09-27 |
| Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis KHK7580 - Secondary Hyperparathyroidism | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 13 | 2014-05-01 | 2015-03-05 |
| EC17 for Intraoperative Imaging for Parathyroidectomy EC17 - Primary Hyperparathyroidism | Phase 1 | Completed | University of Pennsylvania | 10 | 2013-11-01 | 2018-07-03 |
| Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis KHK7580 - Hyperparathyroidism | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 20 | 2013-08-01 | 2017-03-03 |
Showing 20 of 44. Sign in to see all of them.
Hyperparathyroidism, Secondary (16) · Hypoparathyroidism (9) · Parathyroid Neoplasms (8) · Breast Neoplasms (6) · Hyperparathyroidism (6) · Renal Insufficiency, Chronic (6) · Carcinoma, Non-Small-Cell Lung (5) · DiGeorge Syndrome (5) · Esophageal Neoplasms (5) · Hyperparathyroidism, Primary (5) · Prostatic Neoplasms (5) · Thyroid Neoplasms (5) · Urinary Bladder Neoplasms (5) · Carcinoma, Renal Cell (4) · Colonic Neoplasms (4)
Endocrine System Diseases (43) · Hyperparathyroidism (18) · Male Urogenital Diseases (15) · Urogenital Diseases (15) · Female Urogenital Diseases (14) · Female Urogenital Diseases and Pregnancy Complications (14) · Urologic Diseases (14) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Kidney Diseases (12) · Musculoskeletal Diseases (10) · Nutritional and Metabolic Diseases (10) · Chronic Disease (9) · Disease Attributes (9)
etelcalcetide hydrochloride (4) · Cinacalcet (2) · Niacinamide (2) · Thymus Extracts (2) · Trastuzumab (2) · belinostat (2) · 1 alpha-hydroxyergocalciferol (1) · Acetaminophen (1) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Bortezomib (1) · Calcifediol (1) · Cyclosporine (1) · Cyclosporins (1) · Dacarbazine (1)
Sumitomo Pharma Switzerland GmbH (4) · Amgen (3) · KAI Pharmaceuticals (2) · Kyowa Kirin Co., Ltd. (2) · National Cancer Institute (NCI) (2) · OPKO Health, Inc. (2) · OPKO IP Holdings II, Inc. (2) · Shanghai Hengrui Pharmaceutical Co., Ltd. (2) · Shire (2) · Valerio Therapeutics (2) · Washington University School of Medicine (2) · Aevi Genomic Medicine, LLC, a Cerecor company (1) · Amorphical Ltd. (1) · Chugai Pharmaceutical (1) · Endocrinology Research Centre, Moscow (1)
United States (29) · China (4) · Germany (4) · United Kingdom (4) · Canada (3) · Australia (2) · Denmark (2) · Hungary (2) · Israel (2) · Japan (2) · Poland (2) · Belgium (1) · Lithuania (1) · Netherlands (1) · Russia (1)
M. Louise Markert, MD, PhD (3) · Joel Melnick, MD (2) · Adam Hardies (1) · Andrew Poklepovic, MD (1) · Anthony W. Tolcher, MD (1) · Christopher R McHenry, MD (1) · Cornelis J. A. Punt, MD, PhD (1) · Daniel O Young, MD (1) · Daniel W Coyne, M.D> (1) · Einat Dekel, DVM (1) · Gregory Bell, MD (1) · Jeremy Mussallem (1) · Ken Nedd, M.D. (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 15100156, PMID 17284531, PMID 23607606, PMID 40576086, PMID 15100681, PMID 18155964, PMID 18333898, PMID 18385391, PMID 19776051, PMID 20145168, PMID 20978268, PMID 22590644, PMID 32416981, PMID 32647975, PMID 34774334, PMID 35138562, PMID 35690720, PMID 37120522
K12HD043494 (4), R01AI047040 (4), R01AI054843 (4), 2015 (2), R56AI047040 (2), U01CA076576 (1)